After the Federal Circuit’s denial last month of Regeneron’s motion for an injunction pending appeal, seeking to prevent Amgen from ...
Biosimilar aflibercept (P041) demonstrated comparable safety and efficacy to the originator aflibercept (Eylea) in treating patients with retinal conditions like neovascular age-related macular ...
PulseSight plans to submit a phase I clinical trial authorization (CTA) by the end the year, to be closely followed by a phase II proof-of-concept to demonstrate the efficacy and the safety of its ...
Study points to approach to improving anti-VEGF therapy for all wet AMD patients, and help subset of patients who lose vision ...
Dr Garg highlights new data showing that high-dose aflibercept could effectively extend treatment intervals, reducing the burden on patients, particularly working-age adults with busy schedules. Of ...
Outlook Therapeutics' Lytenava has become the first ophthalmic formulation of VEGF inhibitor bevacizumab to be cleared for ...
Approval based on Phase 3 data showing significantly more children aged 1 to 11 years on Dupixent achieved histological disease remission at 16 ...
SOUTH SAN FRANCISCO, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a ...
The nearer-looming threat of a biosimilar from Amgen Inc. to heavyweight Regeneron Pharmaceuticals Inc.’s age-related macular ...
Despite disappointing third-quarter results for Regeneron’s high-dose Eylea injection, analysts continued to be cautiously ...
News Medical on MSN1d
Scientists determine why some patients don't respond well to wet macular degeneration treatment: New drug may bridge gapA study from researchers at Wilmer Eye Institute, Johns Hopkins Medicine explains not only why some patients with wet ...
Oculis has multiple late-stage programs and catalysts. Click here to find out why I think OCS stock looks attractive.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback